Evidence-Based Complementary and Alternative Medicine / 2020 / Article / Fig 1

Research Article

Fortified S-Allyl L-Cysteine: Animal Safety, Effect on Retinal Ischemia, and Role of Wnt in the Underlying Therapeutic Mechanism

Figure 1

The optimal and safe cellular concentration of fortified SAC on ischemia-induced cell viability as evaluated by MTT assay and a cellular ischemia-like model (i.e., OGD) for 1 day. (a) The viability (%) of cells that were cultivated in culture medium plus one hour of pre-OGD administration of Vehicle or SAC: Vehicle + OGD, SAC 0.1 mM + OGD, SAC 0.3 mM + OGD, SAC 0.5 mM + OGD, and SAC 1 mM + OGD were recorded. As compared with the control group (set as 100%; cells cultivated in culture medium containing vehicle, Vehicle + DMEM), the Vehicle + OGD treatment resulted in significant decrease of cellular viability (). This decrease was countered by SAC treatment that resulted in a dosage related and significant (; at 0.1∼1 mM) attenuation of the OGD-induced cellular injury. (b) The efficiency of SAC on the cells in culture medium plus one hour of pre-OGD administration of Vehicle or SAC: Vehicle + OGD, SAC 1 mM + OGD, SAC 10 mM + OGD, and SAC 100 mM + OGD were measured, in terms of cellular viability (%). As compared with the control group, the Vehicle + OGD treatment resulted in a significant decrease of cellular viability (). However, this decrease was attenuated by SAC treatment, but it only resulted in significant (; at 1 mM) attenuation of the OGD induced cellular injury. Note. 1 mM is equivalent to 0.0018 mg/day in animal tests. SAC, S-allyl L-cysteine; OGD, oxygen-glucose deprivation.
(a)
(b)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.